Furthermore, Tarceva in combination with chemotherapy is the first treatment in over a decade to have shown a significant survival benefit in treating patients with pancreatic cancer. It is approved in the US in combination with gemcitabine for the first line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer and in the EU for treatment of metastatic pancreatic cancer. Since its initial launch three years ago, Tarceva has been used to treat more than 250,000 patients and has been approved in over 80 countries worldwide.
About Roche
Information about the Roche Group is available on the Internet at http://www.roche.com
All trademarks used or mentioned in this release are protected by law.
References
---------------------------------
[1] Miller V et al. Abstract LBA8002 presented at ASCO 2009 Annual Meeting, Orlando, US.
[2] Sandler A, et al. N Engl J Med. 2006:355; 2542-50.
[3] Sandler AB et al. J Thor Oncol 2008; 3 (1) Supplement 4, S283.
[4] Cappuzzo F et al. Abstract 8001 presented at ASCO 2009 Annual Meeting, Orlando, US.
[5] Garcia M et al. Global Cancer Facts & Figures. Atlanta, GA: American Cancer Society, 2007.
[6] Allen J et al. J Natl Compr Canc Netw 2008; 6(3): 285-93.
For further information please contact: Roche Group Media Relations, Phone: +41-61-688-8888 / e-mail: basel.mediaoffice@roche.com - Daniel Piller (Head), - Alexander Klauser, - Martina Rupp, - Claudia Schmitt, - Nina Schwab-Hautzinger; Anna Gray, Galliard, Tel Direct: +44-(0)20-7663-2271, Mobile: +44-(0)7590-711189, email: agray@galliardhealth.com
